Glaukos Corporation (NYSE:GKOS) Receives $134.67 Consensus PT from Analysts

Glaukos Corporation (NYSE:GKOS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $134.67.

GKOS has been the subject of a number of recent research reports. BTIG Research restated a "buy" rating on shares of Glaukos in a report on Monday. Mizuho decreased their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Morgan Stanley decreased their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price target on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $160.00 to $86.00 in a report on Thursday, May 1st.

Hedge Funds Weigh In On Glaukos

Large investors have recently added to or reduced their stakes in the business. Bessemer Group Inc. lifted its position in Glaukos by 133.9% in the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 158 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Glaukos during the 4th quarter worth approximately $16,910,000. Harbor Capital Advisors Inc. lifted its position in shares of Glaukos by 59.5% during the 1st quarter. Harbor Capital Advisors Inc. now owns 39,132 shares of the medical instruments supplier's stock worth $3,851,000 after buying an additional 14,593 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Glaukos by 606.7% in the 4th quarter. Teacher Retirement System of Texas now owns 20,247 shares of the medical instruments supplier's stock worth $3,036,000 after buying an additional 17,382 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Glaukos by 35.2% in the 1st quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier's stock worth $485,000 after buying an additional 1,283 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Price Performance

NYSE GKOS traded up $0.25 on Friday, hitting $98.51. 1,130,609 shares of the company's stock were exchanged, compared to its average volume of 747,736. The stock has a 50-day moving average of $97.75 and a 200-day moving average of $113.47. The company has a current ratio of 6.49, a quick ratio of 5.62 and a debt-to-equity ratio of 0.09. Glaukos has a 52 week low of $77.10 and a 52 week high of $163.71. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of -41.57 and a beta of 0.82.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. The company had revenue of $106.66 million during the quarter, compared to analysts' expectations of $102.78 million. During the same period in the prior year, the company earned ($0.70) EPS. Glaukos's revenue was up 24.6% compared to the same quarter last year. Analysts expect that Glaukos will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.